؉ cells were purified in bulk from apheresis-collected cells of children with cancer using monoclonal antibody (MoAb) and magnetic beads (Baxter ISOLEX system). To improve the purity of the final product for possibly better tumor cell purging and to make the manufacturer's original procedure more cost-effective, we incubated the cells for 30 min with l-phenylalanine methylester hydrochloride (PME) to reduce the cell number by removing contaminating granulocytes and monocytes in the initial step before incubation with MoAb. Our modification prevented nonspecific interactions between MoAb and magnetic beads, and thereby saved expensive materials for purification. A total of 40 purifications were performed with samples containing a mean of 3.1 × 10 9 blood cells mobilized from 15 children by chemotherapy plus granulocyte colony-stimulating factor (G-CSF). The entire purification procedure, from the end of apheresis to storage, was completed within 5 h. After incubation with PME and double-layered (40/60%) Percoll separation, the number of CD34 + cells was reduced to 48 ؎ 29%, which suggests the possibility that half of the CD34 ؉ cells in the inoculum were nonclonogenic in the hematopoietic progenitor assay. PME/Percoll-treated cells were then subjected to a final isolation procedure with MoAb according to the manufacturer's suggestions, and 52 ؎ 42% and 32 ؎ 22%, respectively, of the CFU-GM and CD34
gest that our modified purification procedure with PME is useful for the initial reduction of cell numbers to save costly materials, and that cells isolated by this procedure can be directly used in clinical transplantation procedures. Keywords: peripheral blood stem cells; CD34 ϩ cells; purification; transplantation; l-phenylalanine methyl ester Cells that are positive for the CD34 antigen include virtually all hematopoietic precursors that can be measured by in vitro methods, including long-term culture initiating cells (LTC-IC) and lineage committed colony-forming cells. Mobilized peripheral blood is a rich source of CD34 ϩ cells, and the content often exceeds that in bone marrow. 1 Interest in the use of peripheral blood stem cell (PBSC) preparations as a replacement for bone marrow transplant has steadily increased over the past few years. 2, 3 Recently, it has been shown that an effective and low tumor-burden form of hematopoietic support for cancer patients undergoing myeloablative chemotherapy ('indirect purging') is possible through the use of purified CD34 ϩ cells. [4] [5] [6] [7] For a clinical therapeutic procedure to be effective in depleting tumor cells in autografts and T cells in allografts, CD34
ϩ cells need to be extremely pure. However, the wider application of transplants with CD34 ϩ cells has been limited by procedure-related costs, mostly related to the use of monoclonal antibody (MoAb) and immunomagnetic beads.
In this study, we modified the manufacturer's original protocol using anti-CD34 MoAb and magnetic microspheres (ISOLEX system; Baxter, Irvine, CA, USA) to develop a cost-effective and clinically applicable procedure for the bulk purification of CD34 ϩ cells from blood cell grafts. The new procedure includes a short-term incubation with l-phenylalanine methyl ester hydrochloride (PME) 8, 9 before the addition of anti-CD34 antibody to reduce monocytes and granulocytes. We believe that this step should help to reduce the non-specific binding of cells to antibody or immunomagnetic beads, thus improving the separation efficiency and purity of the final products. Moreover, this modification should also reduce the total number of cells required in the costly isolation procedure with MoAb and thereby result in a lower cost. The expansion potential of purified cells was characterized ex vivo in shortand long-term culture. Finally, the engraftment potential of the cells was also tested in autografts after marrow ablative chemotherapy.
Materials and methods

Patients
A total of 15 patients (median age 6 years; range 1-18 years, nine male and six female) with various types of malignant diseases who were scheduled to undergo highdose therapy and autologous PBSC transplantation (PBSCT) were incorporated into this study with a consent form. The diseases included neuroblastoma (three), acute lymphoblastic leukemia (two), yolk sac tumor (two), Wilms' tumor (two), non-Hodgkin's lymphoma (two), rhabdomyosarcoma (one), retinoblastoma (one), malignant teratoma (one) and peripheral neuroectodermal tumor (one). The rationale for performing the isolation procedure, rather than performing an autograft with unmanipulated cells, included the potential risk of cancer cell contamination (n ϭ 11) and graft volume overload (n ϭ 4), which is likely to produce an additional risk at graft infusion. 8 A total of 40 aphereses were performed in the recovery phase of consolidation chemotherapy which included treatment with 50-200 g/m 2 of granulocyte colony-stimulating factor (G-CSF; filgrastim, Kirin Brewery, Tokyo, Japan). General guidelines for initiating apheresis were leukocyte and platelet counts of Ͼ5 × 10 9 /l and Ͼ100 × 10 9 /l, respectively, based on our previous publications. 10 To determine the clinical value of the number of CFU-GM or CD34 ϩ cells for predicting engraftment speed after PBSCT, in a separate single-institute experience with 55 children we analyzed the correlation between hematopoietic recovery and engraftment parameters, including the numbers of CFU-GM and CD34 ϩ cells. In this analysis, 34 patients were diagnosed with acute lymphoblastic leukemia (ALL), five were acute nonlymphocytic leukemia (ANLL), four were neuroblastoma, four were brain tumor, and the others were solid tumors. Thirty-two patients were male and 23 female. The patients ranged in age from 1 to 18 years (median 7 years). High-dose chemotherapy regimens were identical to those described below.
Apheresis and PME procedure
The details of the procedure for collecting blood cells have been described previously. 10 Briefly, a Fenwal CS-3000 Plus cell separator (Baxter Healthcare Limited, Deerfield, IL, USA) was used with a small-volume collection chamber (SVCC) and a granulocyte separation chamber to process 100-350 ml of blood per kg body weight. Cells were recovered in a 50-ml suspension.
Before isolation of CD34 ϩ cells, blood mononuclear cells were prepared by two steps. First, platelet-rich plasma was removed by low-speed centrifugation and cells were diluted with phosphate-buffered saline without Ca 2ϩ or Mg 2ϩ (PBS; Dulbecco's PBS-, Nissui, Tokyo, Japan) to a concentration of 2-5 × 10 7 /ml. The same volume of 10 mm PME (Terumo Medical Corporation, Elkton, MD, USA) supplemented with 40 U/ml of deoxyribonuclease (Sigma DN-25; Sigma Chemical, St Louis, MO, USA) and 2 mm ethylenediamine tetra-acetate (Sigma E-6635) was then added to the cell suspension, as previously described. 8 The mixture was incubated for 30 min at room temperature and placed on double-layered Percoll (40%/60% Percoll, d ϭ 1.046/1.077). After centrifugation for 25 min at 400 g, the cells in the interface were harvested, washed twice with PBS, and resuspended at 1-2 × 10 7 cells/ml in Hank's balanced salt solution (HBSS, Flow Laboratories, Irvine, UK) with 1% human serum albumin (HSA; Albumin-Midori, Green Cross, Kyoto, Japan). In this step, 95% of the contaminating granulocytes, red blood cells, monocytes, and cell debris were removed from the mononuclear cell fraction.
Isolation of CD34
ϩ cells Subsequent procedures strictly adhered to the manufacturer's suggestions. Cells were incubated with 0.5% human gamma-globulin (Polyglobin N; Bayer Japan, Tokyo, Japan) in PBS for 15 min, washed with PBS containing 1% HSA, and incubated with anti-CD34 monoclonal antibody (9C5) at 10 6 cells/0.5 g. After 30 min of incubation at 4°C with gentle rotation (4/min), cells were washed three times with PBS and resuspended in IMDM with 1% HSA at 1-2 ϫ 10 7 /ml. The anti-CD34 antibody-coated cells were incubated with sheep anti-mouse IgG 1 -coated microspheres for 30 min with slow rotation. The rosetted cells were collected by a magnet using an ISOLEX system (Baxter) or MPC-6 (Dynal, Oslo, Norway). Finally, the cells were incubated with 200 U/ml of chymopapain (Chymocell-R; Baxter) for 15 min at 37°C, and isolated from the released beads by a magnet. We divided some samples into two portions and compared the purity of CD34 ϩ cells after this procedure between with and without PME treatment.
Cryopreservation of CD34
ϩ cells
Some of the purified CD34 ϩ cells were used in cell evaluation experiments. The remaining cells which were used for clinical transplantation were resuspended in IMDM supplemented with 10% autologous serum, as previously reported. 10 Cells were slowly mixed with an equal volume of a freezing solution containing 8% human albumin, 12% HES and 10% DMSO to give final concentrations of 5% DMSO, 6% HES and up to 5 × 10 7 cells/ml. Cells were transferred to 5-ml polypropylene tubes and then placed directly in an electric freezer that maintained a temperature of Ϫ135°C (Sanyo Electric, Tokyo, Japan). The cells were stored in the same freezer until use.
Flow cytometry analysis
Sample cells were taken before and after each step in the separation and adjusted to 1 × 10 6 cells/ml in IMDM. Aliquots of 0.3-0.5 ml were then transferred in a volume of 1.5 ml of medium with 10% FBS and stored at 4°C until analysis within 48 h. One hundred microliters of cell suspension were added to a test tube (Falcon 2052; Becton Dickinson, Lincoln Park, NJ, USA) for staining and as a control. Staining was performed in the test tube by adding phycoerythrin (PE)-conjugated CD34 antibody (anti-HPCA-2 antibody, Becton Dickinson) at a concentration of 1 g antibodies/10
6 cells. PE-mouse IgG 1 was used as a control. After 30 min of incubation in the dark, cells were washed twice and resuspended in PBS containing 1% bovine serum albumin (BSA). Red blood cells in the sample were lysed with a solution of 0.826% (w/v) NH 4 Cl, 0.1% KHCO 3 , and 0.004% EDTA-4Na. Samples were analyzed with a FACScan flow cytometer (Becton Dickinson). A total of 20 000 events were counted to identify the mononuclear cell fraction. The flow cytometric data were analyzed using a gated analysis via a set of SSC-FL parameters for CD34 ϩ cells to calculate the percentage of positive cells. 11 
Hematopoietic progenitor cell assay in methylcellulose
Colony-forming cells were incubated in methylcellulose cultures supplemented with 20% fetal bovine serum (FBS, filtron, Brooklyn, Australia), 450 g/ml of human transferrin (Sigma T-1147), 2 U/ml of recombinant human erythropoietin (Epoetin-alpha; 2 × 10 5 IU/mg protein; Kirin Brewery), 1% deionized delipidated BSA (Calbiochem 12657, Hoechst Japan, Tokyo, Japan), and a combination of recombinant human G-CSF (filgrastim; Kirin), interleukin-3 (Kirin) and stem cell factor (Kirin). These stimulating factors were used at a final concentration of 20 ng/ml, which was the previously determined optimal concentration in our laboratory. Triplicate or quadruplicate cultures were plated in volumes of 0.4 ml in 24-well tissue culture plates (Corning 258201, New York, NY, USA) that were then placed in an ESPEC N 2 -O 2 -CO 2 BNP-110 incubator (Tabai ESPEC, Osaka, Japan), which maintained a humid atmosphere of 5% carbon dioxide, 5% oxygen, and 90% nitrogen at 37°C. Plates were incubated for 13-15 days and three types of colonies, including colony-forming unit for granulocyte-macrophage (CFU-GM), burst-forming unit for erythroid (BFU-E), and colony-forming unit for mixed lineage (CFU-mix), were counted using an inverted microscope. The mean number of colonies in four wells was calculated. The plating efficiency (%) of CD34 ϩ cells was calculated as follows: (total number of colonies/number of CD34 ϩ cells plated) × 100.
Long-term culture (LTC)
LTC was performed as previously described with minor modifications. 12 Briefly, the stromal layer established from normal bone marrow MNC was removed by adding 0.25% trypsin (Handaibiken, Suita, Japan) and then subcultured at 1 × 10 5 /ml in 24-well plates (Corning 258201). After 3 days of incubation, the plates were irradiated at a dose of 15 Gy. The following day, purified CD34 ϩ cells were inoculated at 2 × 10 3 cells/well into plates containing the irradiated stromal layer, resulting in a final volume of 2 ml LTC medium. At the fifth week of culture, both nonadherent and adherent cells were harvested from each well by adding 0.25% trypsin. The cells were assayed for CFCs in methylcellulose culture as described above, and the number of total CFCs (CFU-GM, BFU-E, and CFU-mix) obtained was considered LTC-IC.
Expansion culture of CD34
Purified blood CD34 ϩ cells were cultured and expanded in IMDM supplemented with 20% FBS, 1% BSA, 450 g/ml transferrin, IL-3 (20 ng/ml), SCF (20 ng/ml), interleukin-6 (50 ng/ml; Ajinomoto, Tokyo, Japan), and Epo (2 IU/ml). The cells (1000 cell/ml/well) were incubated in 24-well culture plates (Corning 258201) and 1 ml of fresh medium was added to the wells at day 7 of culture. Every 1 or 2 days, the cells in each well were harvested, counted, and then inoculated into the methylcellulose culture system. The changes in the number of cells per well and the CFU-GM output from 1000 CD34 ϩ cells were monitored for 14 days.
Transplantation of purified CD34
A total of 14 patients underwent autografts with CD34 14 These protocols do not incorporate total body irradiation (TBI) and all of the regimens are considered marrow-ablative. Thirty-six hours after completion of the cytoreductive regimen, the cells were rapidly thawed at 37°C and promptly infused into the patients through a central venous catheter without post-thaw washing. No further specific antileukemia therapy was given after PBSCT.
Statistics
Statistical significance was evaluated by the non-parametric Wilcoxon test. The correlation between the log number of infused CD34 ϩ cells or CFU-GM and the number of days required to achieve an absolute neutrophil count (ANC) Ͼ0.5 × 10 9 /l or platelet count Ͼ20 or 50 × 10 9 /l was analyzed using a standard linear regression model.
Results
Patients and apheresis
A total of 40 courses of apheresis were performed in 15 patients (two to five collections per patient) without any particular complications. On the day of apheresis, 2.4 Ϯ 2.3% (mean Ϯ standard deviation; s.d.) of peripheral blood mononuclear cells were CD34-positive and there were 2118 Ϯ 2776 CFU-GM/ml. The mean volume of blood processed per apheresis was 293 ml/kg (range 114-400). The mean numbers of harvested and treated mononuclear cells from these patients were 4.8 Ϯ 4.0 × 10 9 (1.1-23 × 10 9 ) and 3.1 Ϯ 1.8 × 109 (0.8-9.4 × 10 9 ), respectively. Among these 15 patients, 14 subsequently underwent an autograft with purified CD34 ϩ cells. One patient was removed from the study because of disease progression.
Purification of CD34 ϩ cells
The entire purification procedure, from obtaining apheresis bags to storage, was completed within 5 h, and the results are summarized in Table 1 . After PME treatment with Percoll centrifugation, the number of cells was reduced to 46 Ϯ 25% (range 17-108) of the initial inoculum in the bags. Recovery rates of CFU-GM and CD34 ϩ cells were, respectively, 96 Ϯ 39% (34-167) and 48 Ϯ 29% . In comparison to the starting population of MNC, recovery rates of CFU-GM and CD34 ϩ cells after the completed purification procedure were, respectively, 52 Ϯ 42% (3-189) and 32 Ϯ 22% (6.3-84). When the calculation was limited to cell recovery immediately before and after immunomagnetic isolation, the recovery rates of CFU-GM and CD34 ϩ cells were, respectively, 54% and 67%. The use of PME significantly increased the purity of CD34 ϩ cells in samples from selected patients (Figure 1) , whereas there were no significant relationships between the percentages of CD34
ϩ cells in the sample products and the increase in purity.
Characterization of CD34
We tested the growth of isolated CD34 ϩ cells in response to various combinations of CSFs (Figure 2) . The plating efficiency of isolated CD34 ϩ cells in methylcellulose culture was 33 Ϯ 13% in the presence of G-CSF, IL-3 and SCF, and LTC-IC were detected at a mean frequency of 1/200 CD34 ϩ cells (n ϭ 10) after separation. When CD34 ϩ cells were expanded in liquid suspension culture, the number of cells increased up to 120-fold and the number of CFU-GM increased 50-fold.
Engraftment with purified CD34 ϩ cells
The characteristics and engraftment data of the 14 transplanted patients are shown in Table 2 . The mean volume of the grafts the patients received was 8.3 ml (range 3-70 ml), and no adverse effects directly related to graft infusion were observed. Four patients developed clinically suspected bacterial infection, as evidenced by a CRP value of Ͼ10 mg/dl, and were consequently treated by intravenous drip infusion of broad-spectrum antibiotics and 300 g/m 2 of G-CSF over 1 h to enhance hematopoietic recov- Data from 40 purifications are shown as the mean Ϯ standard deviation. Recovery rates of CFU-GM and CD34 ϩ cells were, respectively, 54% and 67% when the calculation was limited to the isolation procedure with MoAb. MNC ϭ mononuclear cells; CFU-GM ϭ colony-forming unit for granulocyte-macrophage. (PME + IgG) (IgG)
Percentage of CD34+ cells P < 0.01 Figure 1 Comparison of the percentage of CD34 ϩ cells in the final purified products between procedures with PME plus IgG and IgG alone, which was used to block intact Fc-receptors on the cell surface. The percentage of CD34 ϩ cells was significantly higher (P Ͻ 0.01) when cells were isolated with a combination of PME and IgG. NB ϭ neuroblastoma; PNET ϭ peripheral neuroectodermal tumor; T-ALL ϭ acute lymphoblastic leukemia (T cell type); RB ϭ retinoblastoma; RBS ϭ rhabdomyosarcoma; GCT ϭ germ cell tumor; WT ϭ Wilms' tumor; NHL ϭ non-Hodgkin's lymphoma.
platelets Ͼ50 × 10 9 /l), although the number of CD34 ϩ cells correlated with the number of CFU-GM in these 14 patients (P ϭ 0.006).
In 55 pediatric patients who underwent autograft in our institute with unfractionated blood cells containing Ͼ3 × 10 5 CFU-GM/kg, these numbers were, respectively, 13 (7-21) and 16 days. Thus, engraftment for both granulocytes and platelets did not appear to be compromised by the enrichment procedure. In this analysis, we found a significant correlation between the CFU-GM infused per kilogram of the patient's body weight and the time to achieve an ANC of Ͼ0.5 × 10 9 /l (r ϭ Ϫ0.667, P Ͻ 0.001) or a platelet count of Ͼ50 × 10 9 /l (r ϭ Ϫ0.572, P Ͻ 0.001). However, no association was seen between the number of CD34 ϩ cells infused and the speed of hematopoietic recovery.
Discussion
Recent techniques for the positive selection/enrichment of CD34 ϩ cells provide a convenient method for concentrating hematopoietic progenitors while depleting unwanted cells, such as tumor cells in autografts and T lymphocytes in allografts. These methods include panning, immunomagnetic beads and column immunoadsorption systems. [15] [16] [17] [18] In a previous study with a panning procedure using a MoAb-coated flask, we tested the efficacy of our protocol for T cell depletion from apheresis-collected blood cells. The results suggested that the large-scale depletion of T cells through negative selection induces an inevitable loss of stem/progenitor cells. 19 On the other hand, CD34 ϩ cells have been successfully isolated by positive selection. The variability in the purity of the enriched cells and the high cost of commercially available reagent kit systems are major problems which should be resolved before the procedure can be widely applied. This variability may be due to the presence of granulocyte, monocytes, and red cells in the products collected by apheresis. Monocytes are major component cells, and have been shown to cause spontaneous aggregation and non-specific adsorption of antibodies. 20 Since the amount of the reagents used for isolation is directly proportional to the input cells, a decrease in granulocytes and monocytes has the dual advantage of reducing both the variability and cost of the separation procedure.
The lysosomotropic agent PME has been shown to be effective in depleting granulocytes and monocytes. 8, 21 After incubation with PME, the cells were centrifuged on Percoll density gradients to remove red cells, debris and cell aggregates. Thus, the reduction of non-specific binding cells and other interfering cells can be accomplished in a single step. One gram of PME is adequate for processing 2 × 10 10 cells, at an additional cost of only $10. As shown in the in vitro experiment, the purified cells retained their ability to produce nucleated cells and hematopoietic progenitor cells which included LTC-IC after PME treatment; the data obtained with CD34 ϩ cells that were purified without PME treatment in our study were identical to those in previous experiments. 12 Combined with in vivo clinical engraftment data, we confirmed that the engraftment capability of these purified cells was not disturbed. Thus, PME treatment had no toxic effects on purified CD34 ϩ cells. We have no definite explanation for why the engraftment speeds in these patients did not correlate with the number of infused cells, in contrast to the significant correlation between the number of CFU-GM and recovery speed of both ANC and platelets in the historical control group. Although the different threshold dose of CFU-GM in both groups may explain this difference, further investigation will be required to clarify this point. On the other hand, the number of CD34 ϩ cells did correlate with the number of CFU-GM in the purified cell fraction. This result suggests that accessory cells that are contained in unmanipulated cells may have affected the number of CD34 ϩ cells in our study. It is possible that PME may reduce the number of con-taminating tumor cells. 8 The depletion of clonal myeloma cells through the purification of CD34 ϩ cells has been reported using a method which incorporates PME. 22 We did not test whether our procedure provided a relatively tumorfree form of hematopoietic stem cells, due to the lack of individual tumor markers and the paucity of recovered cells. However, we did demonstrate that use of the PME procedure resulted in an increased purity of CD34 ϩ cells, which should result in the better depletion of tumor cells. Concerns regarding the possible damage of stem/progenitor cells or the modification of the surface expression of CD34 antigens by this procedure appear to have been answered by our in vivo and ex vivo data, although a determination of sustained engraftment would require long-term followup of these patients.
In this study, the recovery rate of CD34 ϩ cells after the purification procedure with MoAb was relatively low compared with that in other reports, which have mostly used BM CD34 ϩ cells from adult donors. In a previous study, we showed that the loss of progenitor cells during Percoll separation was negligible. 23 It is possible that the biological properties of blood cells from children are different from those of adult marrow cells. A low percentage and/or a wide range of percentages of CD34 ϩ cells in starting samples can result in an inaccurate determination of the number of CD34 ϩ cells. Moreover, it is also possible that the low recovery rate may have been due to the selective loss of CD34 ϩ cells during PME treatment; 42% of CD34 ϩ cells were lost, compared to only 4% of CFU-GM. Further studies are required to clarify this point. When the calculations were limited to the isolation procedure with MoAb alone, the recovery rate of CD34 ϩ cells was 67%. It is very likely that half of the CD34 ϩ cells, including false-positive cells, in the initial inoculum were nonclonogenic for the hematopoietic progenitor assay.
In conclusion, our data suggest that we have developed a clinically practical technique for the scaled-up processing of blood cells for isolation of CD34 ϩ cells, in which we have modified the manufacturer's original protocol by adding the lysosomotropic agent PME. This technique may be useful for clinical procedures for indirect purging in cancer patients, for T cell depletion in mismatched allografts, and for future gene transduction procedures.
